Allurion Stock Soars 17.27% on Positive Study Results

On May 28, 2025, Allurion's stock surged by 17.27% in pre-market trading, marking a significant rise in investor interest and confidence in the company's recent developments.

Allurion recently presented compelling data from a study involving 1,962 patients in France who were treated with the Allurion Program. The results showed that muscle mass as a percentage of total body weight increased by an average of 6.6%, while fat mass decreased by 11%. This data was presented at the Societe Francaise et Francophone de Chiurgie de l’Obesite et des Maladies Metaboliques (SOFFCO.MM) meeting, highlighting the program's effectiveness in achieving metabolically healthy weight loss.

The company also announced that shipments to France have resumed, and patient treatments are expected to begin next month. This resumption of operations in France is a positive development for Allurion, as it indicates a return to a key market and the potential for increased revenue and patient base.

Dr. Shantanu Gaur, Founder and CEO of Allurion, expressed enthusiasm about the company's return to the French market, emphasizing the benefits of Allurion's focus on metabolically healthy weight loss. The company aims to replicate its previous successes in France and continue to provide innovative solutions for weight management.